Lupin Ltd

Large Cap

Healthcare Sector

reflects a positive outlook for the share price

reflects a neutral outlook for the share price

reflects a negative outlook for the share price

The analysts information is for reference only and does not\n  represents an investment recommendation.

Analyst recommendation reflect the views of analysts who follow and write research reports.

Company Information is an introduction to the company’s business that details what it sell, how it was founded, what their mission is, how they manufacture or source their products, and why they serve customers.

Nomura has a Buy rating on Lupin Ltd, noting an increase in gSpiriva market share to 34%. The company also launched gPredForte, boosting its market share to 17%.

Nomura Maintains Buy Call on Lupin Ltd - 02 May, 2025

Lupin Limited has announced a revised timeline for transferring its API R&D division and OTC Consumer Healthcare business to subsidiaries, now expected by June 30, 2025. This strategic move aims to streamline operations and enhance focus on core areas.

Lupin Updates Timeline for Business Transfers - 30 Apr, 2025

Lupin Limited has successfully reduced the price of the tuberculosis drug pretomanid by 25%, making it available for $169 per treatment course through the Global Drug Facility. This price cut enhances global access to essential TB medicine.

Lupin Reduces Price of Key TB Drug by 25% - 25 Apr, 2025

Lupin Ltd has received USFDA approval for its generic Tolvaptan tablets, granting it 180 days of exclusivity. This marks a significant entry into the nephrology market, with estimated annual sales of $1.47 billion. The product will be manufactured at Lupin's Nagpur facility and is expected to launch soon, enhancing Lupin's market position and revenue potential.

Lupin Secures USFDA Approval for Tolvaptan Tablets - 24 Apr, 2025

Lupin Ltd is making significant strides with the launch of gTolvaptan in the US, gaining market sentiment, while facing challenges from patent rulings and product recalls. The company also enhances its cloud infrastructure and receives NABL accreditation for diagnostics labs.

Lupin's Strategic Moves and Market Developments - 23 Apr, 2025

Lupin Pharmaceuticals Inc, a subsidiary of Lupin Ltd, is recalling 2,724 bottles of clomiPRAMINE hydrochloride capsules due to failed impurity specifications, marking a Class II recall initiated on April 18.

Lupin Pharmaceuticals Recalls Antidepressant Medication - 22 Apr, 2025

Lupin Ltd faces a patent ruling in favor of Astellas Pharma regarding Myrbetriq, with a trial set for 2026. Despite this, Lupin's financials remain strong, with a significant profit increase and positive ratings from brokerages. The company received regulatory approval for its Nagpur facility, indicating ongoing operational compliance.

Lupin Faces Patent Challenges but Maintains Growth - 17 Apr, 2025

Lupin Ltd shares dropped significantly after a US court ruled against them in a patent case involving Myrbetriq, blocking their market access and potentially leading to financial penalties. The ruling is expected to impact future revenue forecasts negatively.

Lupin Faces Setback in Myrbetriq Patent Case - 16 Apr, 2025

Lupin Ltd announced the closure of all outstanding USFDA inspections at its Aurangabad facility with the receipt of an establishment inspection report. Despite a broader drop in pharma stocks due to tariff concerns, analysts remain optimistic about Lupin's market position.

Lupin Receives Positive USFDA Inspection Report - 10 Apr, 2025

Lupin Digital Health has doubled its patient base to 10,000 and aims for 50,000 by year-end. The platform focuses on cardiac rehabilitation and prevention, leveraging partnerships and innovative digital solutions.

Lupin Digital Health Expands Patient Base Significantly - 08 Apr, 2025

Lupin's Q3 FY25 earnings show a 10.6% YoY revenue increase to Rs 5,618.6 crore and a 38.81% rise in net profit to Rs 858.86 crore. The company maintains strong U.S. sales and received multiple FDA approvals, despite facing competitive pressures and currency fluctuations. Promoter stake remains stable at 45.41%, indicating confidence in growth.

Lupin Reports Strong Q3 FY25 Earnings Growth - 06 Apr, 2025

Price to Earnings Ratio or Price to Earnings Multiple is the ratio of the share price of a stock to its earnings per share (EPS). It provides an indication of whether a stock at its current market price is expensive or cheap.

The price/earnings-to-growth ratio, or the PEG ratio, is a metric that helps investors value a stock by taking into account a company's market price, its earnings, and its future growth prospects.

Enterprise value (EV) is the total value of a company, defined in terms of its financing. It includes both the current share price (market capitalization) and the cost to pay off debt (net debt, or debt minus cash).

Alpha measures the amount that the investment has returned in comparison to the market index or other broad benchmark that it is compared against.

Beta measures a stock's volatility, the degree to which its price fluctuates in relation to the overall stock market. In other words, it gives a sense of the stock's risk compared to that of the greater market.

Dividend yield measures the quantum of earnings by way of total dividends that investors make by investing in that company.

The debt-to-total-assets ratio shows how much of a business is owned by creditors (people it has borrowed money from) compared with how much of the company's assets are owned by shareholders.

Operating cash flow (OCF) is a measure of the amount of cash generated by a company's normal business operations. Operating cash flow indicates whether a company can generate sufficient positive cash flow to maintain and grow its operations.

This widget shows the information about the stock's peers in consideration along with the different data for those peers so that the user can compare the stock with the other similar stock and invest accordingly.

Promoter holding is the amount of share of the company that is owned by the promoters. The promoters are the company's founders, who hold a majority stake in the company's capital.

A foreign institutional investor (FII) is an investor or investment fund investing in a country outside of the one in which it is registered or headquartered.

A mutual fund is a pool of money managed by a professional Fund Manager. It is a trust that collects money from a number of investors who share a common investment objective and invests the same in equities, bonds, money market instruments, and other securities.

Retail investors execute their trades through traditional or online brokerage firms or other types of investment accounts. Retail investors purchase securities for their own personal accounts and often trade in dramatically smaller amounts as compared to institutional investors.

This widget shows the bifurcation of stocks based on the percentage of stake with the different types of shareholders.

This widget will help value the stock based on the Price to Earning ratio of the stock and compare the valuation with the industry value and other similar stocks. It even shows the timeline of the valuation of the stock and its highest and lowest valuation over time.
A Time Series data is provided which compares the historical stock PE with Industry PE over the period of 5 years.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

Netprofit is up for the last 4 quarters, 359.43 Cr → 855.16 Cr (in ₹), with an average increase of 20.5% per quarter

This section gives you an insight into how the profit for the company has been for the last few quarters.

Profit Spike

In the last 3 years, LUPIN has outperformed top 5 stocks with highest market-cap in Pharmaceuticals

This section gives you an insight into why this company has been the best in its industry for the last 3 years.

Best in 3 Years

In the last 3 years, LUPIN stock has moved up by 183.1%

This section gives you an insight into the price movement of the stock for the last few quarters.

Price Rise

Revenue is up for the last 4 quarters, 4.99K Cr → 5.82K Cr (in ₹), with an average increase of 4.9% per quarter

This section gives you an insight into how the revenue of the company has moved for the last few quarters.

Revenue Rich

Mutual Funds have increased holdings from 16.92% to 17.55% in Mar 2025 quarter

This section gives you an insight into how the Mutual Funds Holding has changed for the stock over last few quarters.

MF Holding Up

In the last 1 year, Divis Laboratories Ltd has given 54.5% return, outperforming this stock by 30.2%

This section gives you an insight into how the peers have performed as compared to this company in the last 1 year.

Against Peers

Promoters have decreased holdings from 46.95% to 46.92% in Mar 2025 quarter

This section gives you an insight into how the Promoter Holding has changed for the stock over the last few quarters.

Promoter Holding Down

Retail Investor have decreased holdings from 6.26% to 6.20% in Mar 2025 quarter

This section gives you an insight into how the Retail Investors Holding has changed for the stock over last few quarters.

Retail Holding Down

Foreign Institutions have decreased holdings from 22.04% to 21.46% in Mar 2025 quarter

This section gives you an insight into how the FII Holding has changed for the stock over last few quarters.

FII Holding Down

S&P BSE MidCap Select

Nifty Midcap Sel

BSE Mid-Cap

BSE Healthcare

BSE 100

S&P BSE 250 LargeMidCap

Nifty 200

S&P BSE 100 ESG

S&P BSE SEN. N50

BSE 200

Nifty Healthcare

S&P BSE 150 MidCap

Nifty Midcap 50

S&P BSE Momentum

Nifty Alpha 50

Nifty Midcap 100

NIFTY PHARMA

Nifty MidSmallcap 400

Nifty LargeMidcap 250

Nifty 500

Nifty Midcap Liquid 15

S&P BSE 400 MidSmallCap

Nifty Midcap 150

BSE 500

HDFC Balanced Advantage Fund Direct Plan Growth Option

HDFC Large Cap Fund -Direct Plan - Growth Option

Axis Midcap Fund Direct Plan Growth

Nippon India Pharma Fund - Direct Plan - Growth Plan

ICICI Prudential Value Discovery Fund Direct Plan Growth

Lupin Ltd’s net profit jumped 39.48% since last year same period to ₹855.16Cr in the Q3 2024-2025. On a quarterly growth basis, Lupin Ltd has generated 0.3% jump in its net profits since last 3-months.

Name	Value	Action
MACD level (12,26)	-0.61	Bullish
CCI (20)	650.76	Bearish
RSI (14)	49.27	Neutral
Momentum (10)	0.6	Bearish
ADI (14)	18.15	Neutral
Ultimate Oscillator (7,14,28)	22.17	Bearish

Name	Value	Action
SMA (20)	2056.79	Bullish
EMA (20)	2057.7	Bullish
VWMA (20)	2057.1	Bullish
SMA (50)	2059.49	Bearish
EMA (50)	2059.23	Bearish
SMA (200)	2060.19	Bearish
EMA (200)	2064.49	Bearish
KAMA (200)	2060.43	Bearish
DEMA (200)	2055.68	Bullish

Lupin Ltd (LUPIN)

Summary

Overall

Oscillators

Moving Averages